Choose the health content that’s right for you, and get it delivered right in your inbox.
Florida Hospital Cancer Institute - Translational Research Core (FHCI-TRC) supports collaborative research efforts focusing on biological discoveries and effective new approaches that advance the treatment of cancer patients and improve patient care and outcomes.
In January 2018, Florida Hospital approved a research agreement and funding between Bristol-Myers Squibb Company and Florida Hospital pathologist Chung-Che (Jeff) Chang, MD, PhD, with the support of FHCI-TRC.
Certain KRAS mutation subtype(s) may be associated with higher PD-L1 expression and/or worse outcomes in lung adenocarcinoma cases with KRAS mutations. The aim of this project is to correlate the degree of PD-L1 expression (based on a composite scoring system considering both staining intensity and % of tumor cells) by PD-L1 IHC 28-8 pharmDx assay (Dako, CA) with the various KRAS mutation subtypes in codons 12 and 13. Dr. Chang will also evaluate if the degree of PD-L1 expression and/or certain subtype(s) of KRAS mutation may impact outcomes (survivals and/or pattern of metastasis) of lung adenocarcinoma patients with KRAS mutations.
The results of the proposed study with a large cohort (n= 297 lung cancer patients, identified between 2011 and 2015 at Florida Hospital) of lung adenocarcinoma patients with KRAS mutations can confirm the preliminary observation by Garon et al that KRAS mutations are associated with the higher degrees of PD-L1 expression. More importantly, the results may define which subtype(s) of KRAS mutations is/are particularly associated with a high degree of PD-L1 expression and/or worse outcomes.